Stress oxidative: Nephrolithiasis and chronic kidney diseases

Minerva Medica

Volumn 104, Issue 1, 2013, Pages 23-30

  Khan, S R ^a  

^a UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Atherosclerosis; Diabetes; Hypertension; Kidney failure, chronic; Metabolic syndrome; Nephrolithiasis; Oxidative stress

Indexed keywords

REACTIVE OXYGEN METABOLITE;

CARDIOVASCULAR DISEASE; CHRONIC KIDNEY DISEASE; COMORBIDITY; CRYSTALLIZATION; DIABETIC NEPHROPATHY; HUMAN; HYPERCALCIURIA; HYPEROXALURIA; HYPERTENSION; HYPOCITRATURIA; METABOLIC SYNDROME X; NEPHROLITHIASIS; NONHUMAN; OXIDATIVE STRESS; PREVALENCE; REVIEW; RISK FACTOR;

CARDIOVASCULAR DISEASES; DIABETIC NEPHROPATHIES; HUMANS; HYPERTENSION; METABOLIC SYNDROME X; NEPHROLITHIASIS; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84876520037     PISSN: 00264806     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. Khan SR. Is oxidative stress, a link between nephrolithiasis and obesity, hypertension, diabetes, chronic kidney disease, metabolic syndrome? Urol Res 2012;40:95-112.
2. Obligado SH, Goldfarb DS. The association of nephrolithiasis with hypertension and obesity: a review. Am J Hypertens 2008;21:257-64. (Pubitemid 351323276)
3. Lieske JC, de la Vega LS, Gettman MT, Slezak JM, Bergstralh EJ, Melton LJ, 3rd et al. Diabetes mellitus and the risk of urinary tract stones: a population-based case-control study. Am J Kidney Dis 2006;48:897-904. (Pubitemid 44895375)
4. Saucier NA, Sinha MK, Liang KV, Krambeck AE, Weaver AL, Bergstralh EJ et al. Risk factors for CKD in persons with kidney stones: a case-control study in Olmsted County, Minnesota. Am J Kidney Dis 2010;55:61-8.
5. Jeong IG, Rang T, Bang JK, Park J, Kim W, Hwang SS et al. Association Between Metabolic Syndrome and the Presence of Kidney Stones in a Screened Population. Am J Kidney Dis 2011;58:383-8.
6. Alexander RT, Hemmelgarn BR, Wiebe N, Bello A, Morgan C, Samuel S et al. Kidney stones and kidney function loss: a cohort study. BMJ 2012;345:e5287.
7. Tibblin G. A population study of 50-year-old men. An analysis of the non-participation group. Acta Med Scand. 1965;178:453-9.
8. Cirillo M, Laurenzi M. Elevated blood pressure and positive history of kidney stones: results from a population-based study. J Hypertens Suppl. 1988;6:S485-486. (Pubitemid 19067382)
9. Cappuccio FP, Strazzullo P, Mancini M. Kidney stones and hypertension: population based study of an independent clinical association. BMJ. 1990;300:1234-6. (Pubitemid 20170675)
10. Cappuccio FP, Siani A, Barba G, Mellone MC, Russo L, Farinaro E et al. A prospective study of hypertension and the incidence of kidney stones in men. J Hypertens. 1999;17:1017-22. (Pubitemid 29322191)
11. Kim YJ, Park MS, Kim WT, Yun SJ, Kim WJ, Lee SC. Hypertension influences recurrent stone formation in nonobese stone formers. Urology 2011;77:1059-3.
12. Akoudad S, Szklo M, McAdams MA, Fulop T, Anderson CA, Coresh J et al. Correlates of kidney stone disease differ by race in a multi-ethnic middle-aged population: the ARIC study. Prev Med 2010;51:416-20.
13. Daudon M, Traxer O, Conort P, Lacour B, Jungers P. Type 2 diabetes increases the risk for uric acid stones. J Am Soc Nephrol 2006;17:2026-33. (Pubitemid 44036187)
14. Sakhaee K. Nephrolithiasis as a systemic disorder. Curr Opin Nephrol Hypertens 2008;17:304-9. (Pubitemid 351535934)
15. Ferder L, Ferder MD, Inserra F. The role of high-fructose corn syrup in metabolic syndrome and hypertension. Curr Hypertens Rep 2010;12:105-12.
16. Jalal DI, Smits G, Johnson RJ, Chonchol M. Increased fructose associates with elevated blood pressure. J Am Soc Nephrol 2010;21:1543-9.
17. Taylor EN, Curhan GC. Fructose consumption and the risk of kidney stones. Kidney Int 2008;73:207-12.
18. Rule AD, Roger VL, Melton LJ, 3rd, Bergstralh EJ, Li X, Peyser PA et al. Kidney stones associate with increased risk for myocardial infarction. J Am Soc Nephrol 2010;21:1641-4.
19. Khan SR. Hyperoxaluria-induced oxidative stress and antioxidants for renal protection. Urol Res 2005:33:349-57. (Pubitemid 41752056)
20. Droge W. Free radicals in the physiological control of cell function. Physiol Rev 2002;82:47-95. (Pubitemid 34654215)
21. Kamata H, Hirata H. Redox regulation of cellular signalling. Cell Signal. 1999;11:1-14. (Pubitemid 28546635)
22. Randall A. The Origin and Growth of Renal Calculi. Ann Surg. 1937;105:1009-27.
23. Tungsanga K, Sriboonlue P, Futrakul P, Yachantha C, Tosukhowong P. Renal tubular cell damage and oxidative stress in renal stone patients and the effect of potassium citrate treatment. Urol Res 2005;33:65-9. (Pubitemid 40487196)
24. Boonla C, Wunsuwan R, Tungsanga K, Tosukhowong P. Urinary 8-hydroxydeoxyguanosine is elevated in patients with nephrolithiasis. Urol Res 2007;35:185-91. (Pubitemid 47312979)
25. Tsao KC, Wu TL, Chang PY, Sun CF, Wu LL, Wu JT. Multiple risk markers for atherogenesis associated with chronic inflammation are detectable in patients with renal stones. J Clin Lab Anal 2007;21:426-31. (Pubitemid 350250413)
26. Mushtaq S, Siddiqui AA, Naqvi ZA, Rattani A, Talati J, Palmberg C et al. Identification of myeloperoxidase, alpha-defensin and calgranulin in calcium oxalate renal stones. Clin Chim Acts 2007;384:41-7. (Pubitemid 47247407)
27. Taylor EN, Fung TT, Curhan GC. DASH-style diet associates with reduced risk for kidney stones. J Am Soc Nephrol 2009;20:2253-9.
28. Umekawa T, Hatanaka Y, Kurita T, Khan SR. Effect of angiotensin II receptor blockage on osteopontin expression and calcium oxalate crystal deposition in rat kidneys. J Am Soc Nephrol 2004;15:635-44. (Pubitemid 38294793)
29. Umekawa T, Tsuji H, Uemura H, Khan SR. Superoxide from NADPH oxidase as second messenger for the expression of osteopontin and monocyte chemoattractant protein-1 in renal epithelial cells exposed to calcium oxalate crystals. BJU Int 2009 BJU Int 2009;104:115-20.
30. Thamilselvan V, Menon M, Thamilselvan S. Oxalate-induced activation of PKC-alpha and -delta regulates NADPH oxidase-mediated oxidative injury in renal tubular epithelial cells. Am J Physiol Renal Physiol 2009;297:F1399-1410.
31. Koul HK, Menon M, Chaturvedi LS, Koul S, Sekhon A, Bhandari A et al. COM crystals activate the p38 mitogen-activated protein kinase signal transduction pathway in renal epithelial cells. J Biol Chem 2002;277:36845-52.
32. Toblli JE, Cao G, Casas G, Stella I, Inserra F, Angerosa M. NF-kappaB and chemokine-cytokine expression in renal tubulointerstitium in experimental hyperoxaluria. Role of the renin-angiotensin system. Urol Res 2005;33:358-67. (Pubitemid 41752057)
33. Khan SR. Crystal-induced inflammation of the kidneys: results from human studies, animal models, and tissue-culture studies. Clin Exp Nephrol 2004;8:75-88. (Pubitemid 38906629)
34. Umekawa T, Chegini N, Khan SR. Oxalate ions and calcium oxalate crystals stimulate MCP-1 expression by renal epithelial cells. Kidney Int 2002;61:105-12. (Pubitemid 34075136)
35. Umekawa T, Iguchi M, Uemura H, Khan SR. Oxalate ions and calcium oxalate crystal-induced up-regulation of osteopontin and monocyte chemoattractant protein-1 in renal fibroblasts. BJU Int 2006;98:656-60. (Pubitemid 44185894)
36. Iida S, Peck AB, Byer KJ, Khan SR. Expression of bikunin mRNA in renal epithelial cells after oxalate exposure. J Urol 1999;162:1480-6. (Pubitemid 29428622)
37. Iida S, Peck AB, Johnson-Tardieu J, Moriyama M, Glenton PA, Byer KJ et al. Temporal changes in mRNA expression for bikunin in the kidneys of rats during calcium oxalate nephrolithiasis. J Am Soc Nephrol 1999;10:986-96. (Pubitemid 29203085)
38. Grewal JS, Tsai JY, Khan SR. Oxalate-inducible AMBP gene and its regulatory mechanism in renal tubular epithelial cells. Biochem J 2005;387:609-16. (Pubitemid 40685694)
39. Moriyama MT, Glenton PA, Khan SR. Expression of inter-alpha inhibitor related proteins in kidneys and urine of hyperoxaluric rats. J Urol 2001;165:1687-92. (Pubitemid 32410289)
40. Suzuki K, Tanaka T, Miyazawa K, Nakajima C, Moriyama M, Suga K et al. Gene expression of prothrombin in human and rat kidneys: basic and clinical approach. J Am Soc Nephrol 1999;10(Suppl 14):S408-411. (Pubitemid 29498591)
41. Wilcox CS, Welch WJ. Oxidative stress: cause or consequence of hypertension. Exp Biol Med (Maywood) 2001;226:619-20.
42. Ignarro LJ, Napoli C, Loscalzo J. Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide: an overview. Circ Res 2002;90:21-8.
43. Armas-Padilla MC, Armas-Hernandez MJ, Sosa-Canache B, Cammarata R, Pacheco B, Guerrero J et al. Nitric oxide and malondialdehyde in human hypertension. Am J Ther 2007;14:172-6. (Pubitemid 46597656)
44. Rodriguez-Iturbe B, Romero F, Johnson RJ. Pathophysiological mechanisms of salt-dependent hypertension. Am J Kidney Dis 2007;50:655-72. (Pubitemid 47454548)
45. Rodriguez-Iturbe B, Vaziri ND, Herrera-Acosta J, Johnson RJ. Oxidative stress, renal infiltration of immune cells, and salt-sensitive hypertension: all for one and one for all. Am J Physiol Renal Physiol 2004;286:F606-616. (Pubitemid 38365077)
46. Chabrashvili T, Tojo A, Onozato ML, Kitiyakara C, Quinn MT, Fujita T et al. Expression and cellular localization of classic NADPH oxidase subunits in the spontaneously hypertensive rat kidney. Hypertension 2002;39:269-74. (Pubitemid 34165227)
47. Schnackenberg CG, Welch WJ, Wilcox CS. Normalization of blood pressure and renal vascular resistance in SHR with a membrane-permeable superoxide dismutase mimetic: role of nitric oxide. Hypertension 1998;32:59-64. (Pubitemid 28324125)
48. Zalba G, Beaumont FJ, San Jose G, Fortuno A, Fortuno MA, Etayo JC et al. Vascular NADH/NADPH oxidase is involved in enhanced superoxide production in spontaneously hypertensive rats. Hypertension 2000;35:1055-61. (Pubitemid 30327257)
49. Grote K, Ortmann M, Salguero G, Doerries C, Landmesser U, Luchtefeld M et al. Critical role for p47phox in renin-angiotensin system activation and blood pressure regulation. Cardiovasc Res 2006;71:596-605. (Pubitemid 44107869)
50. Zhou MS, Hernandez Schulman I, Pagano PJ, Jaimes EA, Raij L. Reduced NAD(P)H oxidase in low renin hypertension: link among angiotensin II, atherogenesis, and blood pressure. Hypertension 2006;47:81-6. (Pubitemid 43177819)
51. Tian N, Moore RS, Phillips WE, Lin L, Braddy S, Pryor JS et al. NADPH oxidase contributes to renal damage and dysfunction in Dahl salt-sensitive hypertension. Am J Physiol Regul Integr Comp Physiol 2008;295:R1858-65.
52. Taylor NE, Glocka P, Liang M, Cowley AW, Jr. NADPH oxidase in the renal medulla causes oxidative stress and contributes to salt-sensitive hypertension in Dahl S rats. Hypertension 2006;47:692-8.
53. Kanwar YS, Sun L, Xie P, Liu FY, Chen S. A glimpse of various pathogenetic mechanisms of diabetic nephropathy. Annu Rev Pathol 2011;6:395-423.
54. Matheson A, Willcox MD, Flanagan J, Walsh BJ. Urinary biomarkers involved in type 2 diabetes: a review. Diabetes Metab Res Rev 2010;26:150-71.
55. Giacco F, Brownlee M. Oxidative stress and diabetic complications. Circ Res 2010;107:1058-70.
56. Kakehi T, Yabe-Nishimura C. NOX enzymes and diabetic complications. Semin Immunopathol 2008;30:301-14.
57. Etoh T, Inoguchi T, Kakimoto M, Sonoda N, Kobayashi K, Kuroda J et al. Increased expression of NAD(P) H oxidase subunits, NOX4 and p22phox, in the kidney of streptozotocin-induced diabetic rats and its reversibity by interventive insulin treatment. Diabetologia 2003;46:1428-1437. (Pubitemid 37297214)
58. Asaba K, Tojo A, Onozato ML, Goto A, Quinn MT, Fujita T et al. Effects of NADPH oxidase inhibitor in diabetic nephropathy. Kidney Int 2005;67:1890-8. (Pubitemid 40577724)
59. Manea A. NADPH oxidase-derived reactive oxygen species: involvement in vascular physiology and pathology. Cell Tissue Res 2010;342:325-39.
60. Brown BG, Zhao XQ, Chait A, Fisher LD, Cheung MC, Morse JS et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-92. (Pubitemid 33126837)
61. Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 2003;1:91-106.
62. Manea A, Manea SA, Gafencu AV, Raicu M. Regulation of NADPH oxidase subunit p22(phox) by NF-kB in human aortic smooth muscle cells. Arch Physiol Biochem 2007;113:163-72.
63. Stefanadi E, Tousoulis D, Papageorgiou N, Briasoulis A, Stefanadis C. Inflammatory biomarkers predicting events in atherosclerosis. Curr Med Chem 2010;17:1690-707.
64. De Rosa S, Cirillo P, Paglia A, Sasso L, Di Palma V, Chiariello M. Reactive oxygen species and antioxidants in the pathophysiology of cardiovascular disease: does the actual knowledge justify a clinical approach? Curr Vasc Pharmacol 2010;8:259-75.
65. Rivera J, Sobey CG, Walduck AK, Drummond GR. Nox isoforms in vascular pathophysiology: insights from transgenic and knockout mouse models. Redox Rep 2010;15:50-63.
66. Drummond GR, Selemidis S, Griendling KK, Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 2011;10:453-71.
67. Curhan GC, Willett WC, Rimm EB, Speizer FE, Stampfer MJ. Body size and risk of kidney stones. J Am Soc Nephrol. 1998;9:1645-52. (Pubitemid 28405072)
68. Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y et al. Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114:1752-61. (Pubitemid 40385531)
69. Soares AF, Guichardant M, Cozzone D, Bernoud-Hubac N, Bouzaidi-Tiali N, Lagarde M et al. Effects of oxidative stress on adiponectin secretion and lactate production in 3T3-L1 adipocytes. Free Radic Biol Med 2005;38:882-9. (Pubitemid 40321080)
70. Silver AE, Beske SD, Christou DD, Donato AJ, Moreau KL, Eskurza I et al. Overweight and obese humans demonstrate increased vascular endothelial NAD(P) H oxidase-p47(phox) expression and evidence of endothelial oxidative stress. Circulation 2007;115:627-7.